Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAA | P10253 | 1/20 | 0.59 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.53 |
| ▸ | MAPT | P10636 | 1/20 | 0.53 |
| ▸ | MMP2 | P08253 | 5/20 | 0.51 |
| ▸ | HRH3 | Q9Y5N1 | 6/20 | 0.50 |
| ▸ | MAOB | P27338 | 1/20 | 0.50 |
| ▸ | MMP3 | P08254 | 5/20 | 0.47 |
| ▸ | HRH2 | P25021 | 3/20 | 0.47 |
| ▸ | HRH1 | P35367 | 3/20 | 0.47 |
| ▸ | MMP1 | P03956 | 1/20 | 0.47 |
| ▸ | MMP9 | P14780 | 1/20 | 0.47 |
| ▸ | MMP13 | P45452 | 1/20 | 0.47 |
| ▸ | TBXAS1 | P24557 | 1/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11767977 | 0.91 | GAA (0.68) | GAAALDH1A1MAPTMMP2HRH3 | |
| SCHEMBL7986752 | 0.86 | ALDH1A1 (0.66) | ALDH1A1MAPTMMP2HRH3MAOB | |
| SCHEMBL31589172 | 0.84 | GAA (0.61) | GAAMMP2HRH3MMP3HRH2 | |
| SCHEMBL5519875 | 0.84 | HRH3 (0.62) | ALDH1A1MAPTMMP2HRH3MAOB | |
| SCHEMBL7384498 | 0.84 | HRH3 (0.59) | ALDH1A1MAPTMMP2HRH3MAOB | |
| SCHEMBL7983991 | 0.82 | HRH3 (0.66) | ALDH1A1MAPTMMP2HRH3MAOB | |
| SCHEMBL5526919 | 0.82 | HRH3 (0.66) | ALDH1A1MAPTMMP2HRH3MAOB | |
| SCHEMBL7387284 | 0.82 | HRH3 (0.66) | ALDH1A1MAPTMMP2HRH3MAOB | |
| SCHEMBL12408526 | 0.82 | HRH3 (0.66) | ALDH1A1MAPTMMP2HRH3MAOB | |
| SCHEMBL8415070 | 0.81 | GAA (0.58) | GAAALDH1A1HRH3MAOBSMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20150133628-A1 | POLYAMINE AND METHOD FOR PRODUCING THEREOF | RHODIA OPERATIONS (FR) | 2015-05-14 | — | — | US | claimed |
| US-20130123542-A1 | POLYAMINE AND METHOD FOR PRODUCING THEREOF | RHODIA OPERATIONS (FR) | 2013-05-16 | — | — | US | claimed |
| EP-2522688-A1 | POLYAMINE AND METHOD FOR PRODUCING THE SAME | Rhodia Operations (FR) | 2012-11-14 | — | — | EP | claimed |
| US-20150133628-A1 | POLYAMINE AND METHOD FOR PRODUCING THEREOF | RHODIA OPERATIONS (FR) | 2015-05-14 | — | — | US | disclosed |
| US-8853457-B2 | Polyamine and method for producing thereof | RHODIA OPERATIONS (FR) | 2014-10-07 | — | — | US | disclosed |
| US-20130123542-A1 | POLYAMINE AND METHOD FOR PRODUCING THEREOF | RHODIA OPERATIONS (FR) | 2013-05-16 | — | — | US | disclosed |
| EP-2522688-A1 | POLYAMINE AND METHOD FOR PRODUCING THE SAME | Rhodia Operations (FR) | 2012-11-14 | — | — | EP | disclosed |
| US-20040147612-A1 | Sulfonamide derivatives | DAVISON JOSHUA ZWICK (US) | 2004-07-29 | — | — | US | disclosed |
| EP-1409452-A1 | SULFONAMIDE DERIVATIVES | ELI LILLY AND COMPANY (US) | 2004-04-21 | — | — | EP | disclosed |
| WO-2002098846-A1 | SULFONAMIDE DERIVATIVES | ELI LILLY AND COMPANY (US) | 2002-12-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040147612-A1 | Sulfonamide derivatives | GRIN1, GRIN2A, GRIA1 | GAA 1132/4885ALDH1A1 365/4885MAPT 2242/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.